An active-comparator trial can inform a relative treatment question without establishing benefit against placebo. This distinction matters for this small crossover study. Primary study
What was studied
Thirty-six people with multiple sclerosis and fatigue entered a blinded randomized crossover comparison of acetyl-L-carnitine and amantadine. The primary fatigue-severity scale favored acetyl-L-carnitine; secondary measures did not significantly differ. Adverse-reaction withdrawals were more frequent during amantadine treatment. Primary report
Our appraisal: relative advantage and absolute benefit are different
Without a placebo period, the study cannot directly show how either treatment compares with no active treatment under otherwise similar conditions. A relative difference may reflect benefit from one intervention, poorer tolerability of the other or a mixture of factors. The design and analysis should distinguish these possibilities as far as the data allow.
Different fatigue scales capture overlapping but nonidentical constructs. The positive primary measure should be reported alongside neutral secondary measures rather than translated into a universal improvement in function or quality of life. Clinical importance also depends on the size and precision of the change, not only its P value.
Withdrawals require careful treatment in a crossover study because a participant may contribute one period but not the other. Reasons, timing and analytical handling can change the interpretation. Differential adverse reactions can also affect masking if participants infer which treatment they received.
The paper is an early comparative signal, not a definitive treatment hierarchy. It should be read with placebo-controlled studies and distinguished from evidence on ordinary L-carnitine. Neither fatigue improvement nor tolerability in a small sample establishes modification of multiple sclerosis itself. This page is an evidence appraisal, not a recommendation to switch prescribed treatment.
Frequently asked questions
Was there a placebo arm?
No.
Which primary measure favored acetyl-L-carnitine?
The Fatigue Severity Scale.
Were secondary outcomes significantly improved?
No significant differences were reported.
Did adverse reactions lead to withdrawals?
Yes.
Does relative advantage prove benefit versus placebo?
No.
Does fatigue relief establish disease modification?
No.
Is ordinary L-carnitine the same tested intervention?
No.